The EPR Effect and its Relevance to Nanomedicine and Cancer Therapeutics
Speaker: Prof. Dr. Alberto A. Gabizon, Hebrew University - School of Medicine - Shaare Zedek MC Oncology Institute, Jerusalem (IL) CLINAM 7/ 2014, 7th Confer...
By: TAUVOD
View original post here:
The EPR Effect and its Relevance to Nanomedicine and Cancer Therapeutics - Video
 Science Daily | Scientists develop novel chemical 'dye' to improve liver cancer imaging Science Daily We are hopeful that this advancement in nanomedicine will lead to safer and more accurate diagnosis of liver cancer. Moving forward, we plan to conduct further pre-clinical safety studies for our contrast agents, with the end goal being clinical ... |
Go here to read the rest:
Scientists develop novel chemical 'dye' to improve liver cancer imaging - Science Daily
PARIS, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN : FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced the trading resumption of its ordinary shares on Euronext in Paris (Euronext Paris) as from 4:00 pm CET.
Trading in the ordinary shares of Nanobiotix was halted at the request of the Company on December 11, 2020 from 9:00 am CET in connection with its previously announced global offering, in order to allow for the confirmation of allocations to investors and for the commencement of trading of the Companys American Depositary Shares on the Nasdaq Global Select Market.
About NANOBIOTIX
Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.
Nanobiotixs novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). Its headquarters are in Paris, France. Nanobiotix has a subsidiary, Curadigm, located in France and the United States, as well as a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.
Important Notice
This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the AMF under number R.20-010 on May 12, 2020 as completed by an amendment to such universal registration document filed with the AMF under number D.0339-A01 on November 20, 2020 (copies of which are available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.
This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares or ADSs of Nanobiotix in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.
A French listing prospectus comprising (i) the 2019 universal registration document filed with the AMF under number R.20-010 on May 12, 2020, as completed by a first amendment to such universal registration document filed with the AMF under number D.0339-A01 on November 20, 2020 and a second amendment to such universal registration document, which will be filed with the AMF on December 11, 2020, and (ii) a Securities Note (Note dopration), including a summary of the prospectus, will be submitted to the approval by the AMF and will be published on the AMFs website at http://www.amf-france.org. Following the filing of the second amendment to the universal registration document with the AMF, copies of Companys 2019 universal registration document, as amended, will be available free of charge at the Companys head office located at 60 rue de Wattignies, 75012 Paris.
European Economic Area
In relation to each Member State of the European Economic Area (each, a Member State) no offer to the public of ordinary shares and ADSs may be made in that Member State other than:
- to any legal entity which is a qualified investor as defined in the Prospectus Regulation;- to fewer than 150 natural or legal persons (other than a qualified investor as defined in the Prospectus Regulation); or- in any other circumstances falling within Article 1(4) of the Prospectus Regulation,
provided that no such offer of ordinary shares and ADSs shall require us or any Underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the Underwriters and the Company that it is a qualified investor as defined in the Prospectus Regulation.
For the purposes of this provision, the expression an offer to the public in relation to any ordinary shares and ADSs in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any ordinary shares and ADSs to be offered so as to enable an investor to decide to purchase any ordinary shares and ADSs, and the expression Prospectus Regulation means Regulation (EU) 2017/1129 (as amended).
France
The ADSs and the ordinary shares have not been and will not be offered or sold to the public in the Republic of France, and no offering of this prospectus or any marketing materials relating to the ADSs and the ordinary shares may be made available or distributed in any way that would constitute, directly or indirectly, an offer to the public in the Republic of France (except for public offerings defined in Article L.411-2 1 of the French Code montaire et financier).
The ordinary shares in the form of ADSs may only be offered or sold in France pursuant to article L. 411-2 1 of the French Code montaire et financier to qualified investors (as such term is defined in Article 2(e) of Regulation (EU) n 2017/1129 dated 14 June 2017, as amended) acting for their own account, and in accordance with articles L. 411-1, L. 411-2 and D. 411-2 to D.411-4, D.744-1 and D. 754-1 and D. 764-1 of the French Code montaire et financier.
This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.
See the article here:
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris - Business Wire
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
In this article, Drug Target Reviews Hannah Balfour discusses the discovery and development of bioenergetic nanocatalysts a new class of drugs for neurodegenerative diseases with Mark Mortenson, Chief Science Officer at Clene Nanomedicine. His company is using an interdisciplinary approach to develop a drinkable, oral suspension of metallic gold nanocrystals to treat a range of neurodegenerative disorders including amyotrophic lateral sclerosis (ALS), Parkinsons and multiple sclerosis (MS). Their lead candidate, CNM-Au8, is currently in Phase II trials in patients with MS and Parkinsons and in Phase II and III trials for the prevention of ALS disease progression.
Mortenson explained that a bioenergetic nanocatalyst is a minute metallic particle in the case of CNM-Au8, made of gold with numerous electrons on its surface that are available for reactions. Depending on the environment, the nanoparticle can either take in excess electrons from its surroundings or give out electrons (referred to as surface plasmons by physicists like Mortenson) oxidising or reducing the local environment in the process to aid cellular processes and reactions.
It is well established that in neurodegenerative diseases, cellular energy production is disrupted. This has been linked to disturbances in glycolytic reactions and mitochondrial dysfunction. In both processes, electron involvement (eg, transfer) is highly important. Mortenson explained that, as a result, Clene scientists theorised that their gold nanocrystals could interact with the brain to provide electrons to facilitate these reactions.
Mortenson revealed: Each of our highly-faceted nanocrystals can exchange millions of electrons on their surface. When someone drinks two ounces (approximately 60ml) of CNM-Au8 they take in over a quadrillion gold nanocrystals, which then travel from their stomach, through the bloodstream and some reach the brain. Each of those gold nanocrystals can act as an electron bank for redox reactions, sharing, as needed, millions of electrons at a rate of, for example, 4,000 a second.
In vitro and in vivo we have shown that these nanocrystals enhance both mitochondrial function and glycolytic reactions. Bioenergetics means we are helping naturally occurring reactions at the cellular and intracellular level that are stressed for some reason, to work better. While they cannot replace the neurons that are already lost, they improve the function of what is left behind.
He explained that their R&D work first started in the energy field of nanotechnology, rather than nanomedicine or the use of nanotech for health. However, as they studied nanocatalysis in polymer electrolyte membrane fuel cells and hydrolysis reactions, they hypothesised that some of their discoveries especially the ability to make clean-surfaced metallic nanocrystals that are highly-faceted and may act as catalysts for reactions also related to biology.
one of the most remarkable aspects of using catalysts, rather than a pharmacological agent, is that they stop working once an equilibrium is reached. Therefore, it is highly unlikely the drug will over- or under-activate a pathway to the point that it becomes dangerous
Mortenson commented: Gold nanoparticles predate our concept of working with them; however, our two Eureka moments were we saw data on the slowed surface flow of electrons on a nanocrystal surface when polluted with a molecular surface residue and when a publication came out in 2010, stating that while 200 plus articles published to date had reported on various toxicities of gold nanoparticles to date, with results all over the map, not a single one had taken into account the method of making the nanoparticles.
What we had discovered by this point, while working on these hydrolysis and fuel cell reactions, was that different manufacturing processes or matricies (what the gold nanocrystals grow on) result in residual particles sticking to the surfaces of the gold nanoparticles. No one had understood that the toxicity was not the gold itself, per se, but rather the residual surface chemistry that was unintentionally or intentionally put there. In some cases, people were very proud of the stability of their gold nanoparticles after they coated them with polyethylene glycol, essentially anti-freeze for your car, but failed to take into account what toxicity that was introducing in biological interactions.
Using the methods we identified initially in our energy studies, we now make highly-faceted, therapeutic, clean-surfaced nanocrystals designed to have a particular interactions with biological targets. The clean surface is the most important thing, because it eliminates toxicity. If the surface is not clean then you will only learn how toxic a nanoparticle is once you go through all the pre-clinical and clinical drug development programmes (in vitro, in vivo, etc) and the efficacy of the nanocrystals also could change dramatically if the surfaces are not clean.
Mortenson revealed: Some of our most exciting results are from Phase II, brain biomarker, proof-of-target effect trials being conducted at the University of Texas, US, called Repair-MS and Repair-PD. In these trials, all participants are receiving CNM-Au8, just at different concentrations. What we are looking at is whether the treatment changes the energy metabolism patterns on the patients magnetic resonance spectroscopy images.
But rather than looking at how protons are stimulated within the magnetic field, we are performing 31P (31-Phosphorous Magnetic Resonance Imaging) spectroscopy and looking at changes in amounts of phosphorus compounds, such as NAD+ (Nicotinamide Adenine Dinucleotide), NADH, PCR, PME, phosphocholine and phosphocreatines. Each patient acts as their own baseline and what we are assessing is, after being on the drug for X number of weeks, is there a change? While the trials have been disrupted by COVID-19, the interim data is fascinating. We are seeing an absolute change in the values of these phosphorus components. What is really exciting is that CNM-Au8 is acting exactly as a catalyst would ie, in those individuals that maybe had too much of certain compounds, they now have less, while those that had too little now have more. Thus far, we have reported data through at least 12 weeks.
In addition, we are seeing this regardless of whether they are Parkinsons or MS patients.
He added that one of the most remarkable aspects of using catalysts, rather than a pharmacological agent, is that they stop working once an equilibrium is reached. Therefore, it is highly unlikely the drug will over- or under-activate a pathway to the point that it becomes dangerous.
We have the capability to work with a variety of different metals, including a really cool gold alloy that cannot be made in nature. What is interesting is that, when utilising these metallic nanocrystals as catalysts in health applications, a difference of a few atoms on the surface can significantly change the energy levels of the electrons. The correct energy level is what allows various reactions to occur.
So, there are numerous potential applications sitting on our shelves. What people who have worked on the CNM-Au8 project have realised is that the impact of these nanocatalysts is beyond just the first three neurodegenerative diseases. In fact, I may be so bold as to say most neurodegenerative diseases could probably benefit from a boost in metabolic activity when it is compromised. There is also a variety of diseases associated with ageing, including cancer, in which there is a metabolic paradigm shift and these could also be targets for Clenes bioenergetic nanocatalysts in the future.
I think we could eventually touch many human beings on the planet if we have enough people and financial capacity. Our company was founded with the hope to help overburdened healthcare systems worldwide with our stable liquid suspensions that may improve both health span and possibly life span.
He added that his entire team is currently focused on the development, clinical testing and scaling up the production of Clenes Au8 lead candidate, so these projects will have to wait.
In the interview, Mortenson explained that two people inspired his thinking and therefore the company. He said that Professor Rustum Roy, who started the Materials Research Laboratory at Pennsylvania State University (Penn State), taught him that the world is far more than he had been taught and, as a result, infinitely more interesting. Rustum introduced him to a whole new way of thinking: the unanswered questions were the impetus for his work.
Dr Roy also introduced Mortenson to Hans-Peter Durr, who was the vice executive director of the Max Planck Institute for Theoretical Physics at Heidelberg, who proceeded to expand Mortensons perspective on quantum physics. These two then introduced and included Mortenson in small discussions with several leading scientific minds and Nobel laureates, at which point Mortenson felt honored to be included!
He realised that his role was to unite the different disciplines of electrochemistry, materials science and physics with biology and to help break down artificial barriers in science even after these individuals passed away. While both passed around 10 years ago now, Mortenson emphasised that they are the reason that Clene strives to think beyond narrow areas of expertise and why the company is where it is now.
Continue reading here:
Developing bioenergetic nanocatalysts to treat neurodegeneration - Drug Target Review
Dataintelo, one of the worlds leading market research firms has rolled out a new report on Nanomedicine market. The report is integrated with crucial insights on the market which will support the clients to make the right business decisions. This research will help both existing and new aspirants for Global Nanomedicine Market to figure out and study market needs, market size, and competition. The report provides information about the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities, and the threats faced by key players.
The report also includes the impact of the ongoing global crisis i.e. COVID-19 on the Nanomedicine market and what the future holds for it. The pandemic of Coronavirus (COVID-19) has landed a major blow to every aspect of life globally. This has lead to various changes in market conditions. The swiftly transforming market scenario and initial and future assessment of the impact are covered in the report.
Request a sample Report of Nanomedicine Market: https://dataintelo.com/request-sample/?reportId=81345
The report is fabricated by tracking the market performance since 2015 and is one of the most detailed reports. It also covers data varying according to region and country. The insights in the report are easy to understand and include pictorial representations. These insights are also applicable in real-time scenarios. Components such as market drivers, restraints, challenges, and opportunities for Nanomedicine are explained in detail. Since the research team is tracking the data for the market from 2015, therefore any additional data requirement can be easily fulfilled.
The scope of the report has a wide spectrum extending from market scenarios to comparative pricing between major players, cost, and profit of the specified market regions. The numerical data is supported by statistical tools such as SWOT analysis, BCG matrix, SCOT analysis, and PESTLE analysis. The statistics are depicted in a graphical format for a clear picture of facts and figures.
The generated report is strongly based on primary research, interviews with top executives, news sources, and information insiders. Secondary research techniques are utilized for better understanding and clarity for data analysis.
The Nanomedicine Market is divided into the following segments to have a better understanding:
By Application:
Segmentation encompasses oncologyInfectious diseasesCardiologyOrthopedicsOthers
By Type:
Quantum dotsNanoparticlesNanoshellsNanotubesNanodevices
By Geographical Regions:
Ask for Discount on Nanomedicine Market Report at: https://dataintelo.com/ask-for-discount/?reportId=81345
The Nanomedicine Market industry Analysis and Forecast 20192026 help clients with customized and syndicated reports holding key importance for professionals requiring data and market analytics. The report also calls for market-driven results providing feasibility studies for client requirements. Dataintelo promises qualified and verifiable aspects of market data operating in the real-time scenario. The analytical studies are carried out ensuring client requirements with a thorough understanding of market capacities in the real-time scenario.
Some of the prominent companies that are covered in this report:
Key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report. Following is the list of key players:
CombimatrixAblynxAbraxis BioscienceCelgeneMallinckrodtArrowhead ResearchGE HealthcareMerckPfizerNanosphereEpeius BiotechnologiesCytimmune SciencesNanospectra Biosciences
*Note: Additional companies can be included on request
Reasons you should buy this report:
Dataintelo provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.
Customized Report and Inquiry for the Nanomedicine Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=81345
About US:
DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry.
Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.
Contact Info:
Name: Alex Mathews
Address: 500 East E Street, Ontario,
CA 91764, United States.
Phone No: USA: +1 909 545 6473
Email:[emailprotected]
Website:https://dataintelo.com
Follow this link:
Nanomedicine Market is Expected to Thrive at Impressive CAGR by 2026 & Top Key Players are Combimatrix, Ablynx, Abraxis Bioscience, Celgene,...
Global Cancer Nanomedicine Market Survey Research Report
The Global Intelligence Insights added a new report Global Cancer Nanomedicine Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016 2024 in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, segmentation and forecasting.
Market Overview:
Cancer Nanomedicine Market to grow from USD 761.85 billion in 2016 and reach USD 918.74 billion by 2020, growing at a CAGR of 4.8% during the forecast period.
The global Cancer Nanomedicine Market report offers a complete overview of the Cancer Nanomedicine Market globally. It presents real data and statistics on the inclinations and improvements in global Cancer Nanomedicine Markets. It also highlights manufacturing, abilities & technologies, and unstable structure of the market. The global Cancer Nanomedicine Market report elaborates the crucial data along with all important insights related to the current market status.
The report additionally provides a pest analysis of all five along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the Cancer Nanomedicine market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.
Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.
Get sample copy of thisreport @ https://www.globalintelligenceandinsights.com/request-sample-1004167
Top Key Players: Abraxis BioScience,Access Pharmaceuticals,Alnylam Pharmaceuticals,Arrowhead Research,BIND Biosciences,Epeius Biotechnologies,Nanobiotix,NanoCarrier,Nippon Kayaku,Samyang,Takeda Pharmaceutical
The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Cancer Nanomedicine market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.
Market Dynamics:
The report analyzes the factors impacting the growth and the current market trends influencing the global Cancer Nanomedicine market. Detailed pricing information with ex-factory prices of various products by key manufacturers form a crucial part of the report. Competition analysis, along with regional government policies affecting the Cancer Nanomedicine market provides a detailed overview of the current status and prospects of the market. The impact of the ever-growing global population, coupled with technological advancements affecting the global Cancer Nanomedicine market is also covered in the report.
Drivers & Constraints:
The report provides extensive information about the factors driving the global Cancer Nanomedicine market. Factors influencing the growth of the Cancer Nanomedicine market, along with technological advancements, are discussed extensively in the report. The current restraints of the market, limiting the growth and their future impact are also analyzed in the report. The report also discusses the impact of rising consumer demand, along with global economic growth on the Cancer Nanomedicine market.
Regional Segment Analysis:
This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Cancer Nanomedicine Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.
Key questions answered in the report include:
What will the market size and the growth rate be in 2026?
What are the key factors driving the Global Cancer Nanomedicine Market?
What are the key market trends impacting the growth of the Global Cancer Nanomedicine Market?
What are the challenges to market growth?
Who are the key vendors in the Global Cancer Nanomedicine Market?
What are the market opportunities and threats faced by the vendors in the Global Cancer Nanomedicine Market?
Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.
The report includes six parts, dealing with:
1.) Basic information;
2.) The Asia Cancer Nanomedicine Market;
3.) The North American Cancer Nanomedicine Market;
4.) The European Cancer Nanomedicine Market;
5.) Market entry and investment feasibility;
6.) The report conclusion.
Reasons for Buying this Report:
This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth
It provides a six-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
TABLE OF CONTENT:
1 Report Overview
2 Global Growth Trends
3 Market Share by Key Players
4 Breakdown Data by Type and Application
5 United States
6 Europe
7 China
8 Japan
9 Southeast Asia
10 India
11 Central & South America
12 International Players Profiles
13 Market Forecasts 2019-2025
14 Analysts Viewpoints/Conclusions
15 Appendixes
Get Up to 20% Discount on this Premium Report @ https://www.globalintelligenceandinsights.com/request-sample-1004167
If you have any special requirements, please let us know and we will offer you the report as you want.
About Us:
Global Intelligence and Insights is one of the top resellers of market research reports, including market intelligence, data solutions, competitive positioning, and custom intelligence to an array of organizations globally. Our customer portfolio includes business organizations from fortune 500 companies, SMEs, start-ups, financial technology start-ups, and venture capitalists. We have an exhaustive database of market research reports provided by more than 20 leading publishers across different industry verticals.
We provide tailored solutions that can be utilized to solve business challenges and problems faced by organizations in different regions. Additionally, our bouquet of solutions assists enterprises in strategic planning and staying ahead of the competition while getting access to extensive market forecast and trend mapping over the future course of time. In addition to the market forecast and other vital components of the market analysis, our reports include in-depth micro-macro analysis of the market, which aids the customers in analyzing the market ecosystem, thus assisting in the existing and new players in the development of strategic plans.
Contact Us:
Global Intelligence Insights
Bruno Abraham
US: +1-571-577-4575
202 Church Street SE,
Suite 301, Leesburg,
VA 20175
[emailprotected]
View original post here:
Cancer Nanomedicine Market Size, Comprehensive Analysis, Development Strategy, Future Plans and Industry Growth with High CAGR by Forecast 2026 |...
UPDATE AVAILABLE ON-DEMAND
Nanomedicine is an application of nanotechnology that deals in the prevention & treatment of diseases in humans. This technology uses submicrometer-sized particles for diagnosis, treatment, and prevention of diseases. Nanomedicines are advantageous over generic drugs in several aspects such as, to reduce renal excretion, improve the ability of drugs to accumulate at pathological sites, and enhance the therapeutic index of drugs. Thus, nanomedicine is used in a wide range of applications that include aerospace materials, cosmetics, and medicine.
The global nanomedicine market was valued at $111,912 million in 2016, and is projected to reach $261,063 million by 2023, growing at a CAGR of 12.6% from 2017 to 2023. The drug delivery segment accounted for nearly two-fifths share of the global market in 2016.
Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/2021
The global market is driven by increase in the development of nanotechnology-based drugs, advantages of nanomedicine in various healthcare applications, and growth in need of therapies with fewer side effects. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth. In addition, growth of healthcare facilities in emerging economies is anticipated to provide numerous opportunities for the market growth.
The vaccines segment is expected to register a significant CAGR of 13.2% throughout the forecast period. The treatment segment accounted for about fourth-sevenths share in the global market in 2016, accounting for the highest share during the forecast period. This is due to the high demand for therapeutics among patient and rise in the incidence of chronic diseases.
The neurological diseases segment is expected to grow at the highest CAGR of 13.9% during the forecast period, owing to high demand for brain monitoring & treatment devices and drugs. The oncological diseases segment accounted for the highest revenue in 2016, with one-third share of the global market, and is expected to maintain its dominance throughout the forecast period.
In 2016, Asia-Pacific and LAMEA collectively accounted for about one-fourth share of the global market, and is expected to continue this trend due to increased adoption of nanomedicines, especially in China, India, and the other developing economies. In addition, rise in investments by key players in the field of nanomedicines is key driving factor of the Asia-Pacific market.
Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/2021
The Major Key Players Are:
The Other Prominent Players Are:
About Us:
Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of Market Research Reports and Business Intelligence Solutions. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa5933 NE Win Sivers Drive#205, Portland, OR 97220United StatesToll Free (USA/Canada):+1-800-792-5285, +1-503-894-6022, +1-503-446-1141UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1-855-550-5975[emailprotected]Web:https://www.alliedmarketresearch.com
A new Research Report published byJCMRunder the titleGlobal Nanorobotics Market(COVID 19 Version)can grow into the worlds most important market which has played an important role in making progressive impacts on the global economy. TheGlobal Nanorobotics MarketReport presents a dynamic vision for concluding and researching market size, market hope and competitive environment. The study is derived from primary and secondary Research and consists of qualitative & Quality analysis. The main company in this Research isBruker, JEOL, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments, EV Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Xidex, Synthace, Park Systems, Smaract, Nanonics Imaging, Novascan Technologies, Angstrom Advanced, Hummingbird Scientific, NT-MDT Spectrum Instruments, Witec, ..
Get Free Sample Report PDF @:jcmarketresearch.com/report-details/1143467/sample
Data sourcing technique we follow: We Used Some Premium Sites to gather data.
Get Up to 40 % Discount on Enterprise Copy@jcmarketresearch.com/report-details/1143467/discount
Note: Regional Breakdown & Sectional purchase Available We provide Pie Charts Best Customize Reports as per Requirements.
Research Methodology:
Primary Research:
We interviewed various key sources of supply and demand in the course of thePrimary Researchto obtain qualitative and quantitative information related to this report. Main sources of supply include key industry members, subject matter experts from key companies, and consultants from many major firms and organizations working on theGlobal Nanorobotics Market.
Secondary Research:
Secondary Researchwas performed to obtain crucial information about the business supply chain, the company currency system, global corporate pools, and sector segmentation, with the lowest point, regional area, and technology-oriented perspectives. Secondary data were collected and analyzed to reach the total size of the market which the first survey confirmed.
Furthermore, the years considered for the study are as follows:
Historical year 2013-2018
Base year 2019
Forecast period** 2020 to 2029
Some Key Research Questions & answers:
What Is impact of COVID 19 onGlobal Nanorobotics Market?
Before COVID 19Global Nanorobotics MarketSize Was XXX Million $ & After COVID 19 Excepted to Grow at a X% & XXX Million $.
Who are the Top Key Players in theGlobal Nanorobotics Marketand what are their priorities, strategies & developments?
Lists of Competitors in Research is:Bruker, JEOL, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments, EV Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Xidex, Synthace, Park Systems, Smaract, Nanonics Imaging, Novascan Technologies, Angstrom Advanced, Hummingbird Scientific, NT-MDT Spectrum Instruments, Witec, ..
What are the Types & Applications of theGlobal Nanorobotics Market?
Applications cover in these Reports Is:Nanomedicine, Biomedical, Mechanical, Others
Types Cover in this Research:Nanomanipulator, Bio-Nanorobotics, Magnetically Guided, Bacteria-Based
Note: Please Share Your Budget on Call/Mail We will try to Reach your [emailprotected]Phone:+1 (925) 478-7203/Email:[emailprotected]
Enquiry for Segment [emailprotected]jcmarketresearch.com/report-details/1143467/enquiry
All percent shares, breaks, and classifications were determined using the secondary sources and confirmed through the primary sources. All parameters that may affect the market covered in this study have been extensively reviewed, researched through basic investigations, and analyzed to obtain final quantitative and qualitative data. This has been the study of key quantitative and qualitative insights through interviews with industry experts, including CEOs, vice presidents, directors and marketing executives, as well as annual and financial reports from top market participants.
Table of Content:
1 Report Summary
1.1 Research Scope
1.2 Key Market Segments
1.3 Target Player
1.4 Market Analysis by TypeNanomanipulator, Bio-Nanorobotics, Magnetically Guided, Bacteria-Based
1.5 Market by ApplicationNanomedicine, Biomedical, Mechanical, Others
1.6 Learning Objectives
1.7 years considered
Place Order to Quick Buy Report @jcmarketresearch.com/checkout/1143467
2 Global Growth Trends
2.1 GlobalGlobal Nanorobotics MarketSize
2.2 Trends ofGlobal Nanorobotics MarketGrowth by Region
2.3 Corporate trends
3Global Nanorobotics Marketshares by key players
3.1Global Nanorobotics MarketSize by Manufacturer
3.2Global Nanorobotics MarketKey players Provide headquarters and local
3.3 Major Players Products / Solutions / Services
3.4 Enter the Barriers in theGlobal Nanorobotics Market
3.5 Mergers, acquisitions and expansion plans
Continue..
About Author:JCMR global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.
Contact Us:JCMARKETRESEARCHMark Baxter (Head of Business Development)Phone:+1 (925) 478-7203Email:[emailprotected]
Connect with us at LinkedIn
Continued here:
Nanorobotics Market to Witness Huge Growth by 2028 | Bruker, JEOL, Thermo Fisher Scientific - The Think Curiouser
Chicago, United States: Global Healthcare Nanotechnology (Nanomedicine) Market Report 2021, Forecast to 2026, The report focuses on encompassing several factors such as global distribution, manufacturers, and various regions. The report has summed up industry analysis size, share, application, and statistics associated with the global Peptide Synthesis market. The report delivers an in-depth competitive landscape, Growth opportunities, market share coupled with product type and applications. The report also estimates comprehensive market revenue along with Growth patterns, and the overall volume of the market.
Crucial information and forecast statistics covered in the Healthcare Nanotechnology (Nanomedicine) Market report will arm both existing and emerging market players with necessary insights to craft long-term strategies as well as maintain business continuity during a crisis such as the ongoing COVID-19 pandemic.
Key players covered in the report include:Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, SmitH& Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Takeda, Ipsen, Endo International,
Request for Sample Report (Including COVID19 Impact Analysis, full TOC, Tables and Figures) of Healthcare Nanotechnology (Nanomedicine) Market @ https://www.reporthive.com/request_sample/2411789
NOTE: Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Healthcare Nanotechnology (Nanomedicine) Market which would mention How the Covid-19 is affecting the Healthcare Nanotechnology (Nanomedicine) Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Healthcare Nanotechnology (Nanomedicine) Players to Combat Covid-19 Impact.Valuable information covered in the Healthcare Nanotechnology (Nanomedicine) Market report has been segregated into key segments and sub-segments.
By Service typeNanomedicineNano Medical DevicesNano Diagnosis
By End useAnticancerCNS ProductAnti-infective
Healthcare Nanotechnology (Nanomedicine) Market: Competition Analysis
The Report Hive Research study presents a comprehensive analysis of global, regional, and country-level players active in the Healthcare Nanotechnology (Nanomedicine) Market. Competitive information detailed in the Healthcare Nanotechnology (Nanomedicine) Market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player.
Important Questions Answered in the Healthcare Nanotechnology (Nanomedicine) Market Report
Key Offerings of the Report
>>>>Get Full Customize Report @ https://www.reporthive.com/request_customization/2411789The report firstly introduced the Healthcare Nanotechnology (Nanomedicine) basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.
Why Go For Report Hive Research?
Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high Growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.
Get in Touch with Us :
Report Hive Research
500, North Michigan Avenue,
Suite 6014,
Chicago, IL 60611,
United States
Website: : https://www.reporthive.com
Email: [emailprotected]
Read the original here:
Healthcare Nanotechnology (Nanomedicine) Market Report Global Industry Size, Segment By Key Companies, Types & Applications And Forecast To 2025 |...
DGAP-News: MagForce AG / Key word(s): Half Year Results30.10.2020 / 08:30 The issuer is solely responsible for the content of this announcement.
MagForce AG Publishes Financial Results for the First Half of 2020 and Operative Highlights
- Very significant increase in European patient inquiries for NanoTherm therapy system for the treatment of glioblastomas
- U.S. focal prostate cancer treatment study: positive findings of Stage 1 confirmed during current Stage - positive treatment results also with the streamlined procedure
- Flexible commercialization models for focal cancer treatment centers in the U.S. in place
Berlin, Germany and Nevada, USA, October 30, 2020 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results for the first half of 2020, ending on June 30, 2020, and operative highlights.
"During the first half of 2020, we have continued to pass several major milestones and have made significant progress both in Europe with our roll-out strategy and the U.S. with the start of the next stage in our pivotal clinical study for the focal ablation of intermediate risk prostate cancer. MagForce continues to cope with the ever-evolving situation around COVID-19, nevertheless I am steadfast in my belief that by pursuing a strategy of expansion with sustainable partnerships in Europe and providing NanoTherm therapy in the U.S. to patients suffering from prostate cancer, MagForce is well positioned for the future." commented Ben Lipps, CEO of MagForce AG and MagForce USA, Inc. "At the same time, MagForce today is in a better operational position than ever before in the company's history - the number of brain tumor treatments in Europe is increasing significantly and sustainably, the interest of clinics is really high, and in the U.S. our pivotal study for the focal treatment of prostate cancer proves that our therapy is achieving the very good treatment results we had hoped for."
Operative Highlights
Europe - Brain Cancer Treatment
In the first half of 2020 we received a very significant increase in patient inquiries for NanoTherm therapy - a strong indication of how convinced MagForce's partner clinics are of the therapeutic option and its use for the treatment of glioblastomas. It can be assumed that the number of treatments will continue to increase sustainably. The global opportunity for treating glioblastoma is approximately 160,000 patients per year - indicating that this procedure has a significant global market opportunity of approximately four billion Euros per year for this treatment.
All company activities in Europe are aimed at further increasing awareness of the NanoTherm therapy system and making it available to patients. For example, the MagForce's 'NanoTherm Therapy School', a practice-oriented, unique and versatile application training course for the use of the NanoTherm therapy system for the treatment of glioblastoma, continues to be very successful. The goal of the comprehensive application training is to certify surgeons in the use of our innovative NanoTherm technology. Just this month, the third session, Module B - Part II, in the training was concluded. As seen in the registration numbers and also in participant feedback, interest in MagForce's innovative therapy is greater than ever before.
As part of the Company's European roll-out strategy, further installations of NanoActivator devices in partner hospitals in Spain and Italy are planned. The opening of these additional centers, which were planned for the second half of 2020, will be further delayed due to the enormous impact that the COVID-19 pandemic is unfortunately currently having again in these countries. However, interest from other European countries has been seen and MagForce will continue its roll-out strategy in the coming months. In addition, in Germany, the official opening of the latest NanoTherm therapy center at the Hufeland clinic in Mhlhausen is scheduled for November and, MagForce is planning another NanoTherm treatment center in Germany. All this will help us to achieve the treatment goal for 2021 and triple the number of commercial treatments compared to 2020.
Commercial Model for Brain Cancer Treatments in Europe: 'Plug-and-Treat'
To make the NanoTherm therapy system more assessable to clinics, MagForce has developed a container 'plug-and-treat' solution, which has become the delivery standard in Germany as well as in European countries. The pre-installed containers only require a dedicated outdoor space and a standard three phase current connection and are transported to the clinic by truck. MagForce delivers complete regulatory and technical documentation to the clinic administration in advance so that official approvals can be issued quickly. With this mobile 'plug-and-treat' solution the Company has been able to significantly shorten the time to start patient treatment in new centers. Currently, no more than three months from the date of order placement to commission a new NanoTherm treatment center in Germany or other European countries is expected. MagForce currently still has materials in stock for the new production of three additional devices, which will be manufactured on schedule, if required.
USA - Focal Prostate Cancer Treatment
Mirroring results on the first stage of the focal prostate cancer treatment study, treatment results in the current stage of the study, with the streamlined procedure, show only minimal treatment-related side effects that are tolerable and similar to those of biopsies. The ablation analysis showed a very well-defined ablation and cell death in the area of the nanoparticle depot, as observed in previous preclinical studies. This was expected, but is nevertheless very encouraging, as patients can be treated much faster. It is obvious that the streamlined study protocol will benefit patients by completing the entire treatment within one day, thus minimizing the burden of repeated visits to the treating physician.
We continue to expect to generate sufficient data in the fourth quarter of 2020 to confirm that our streamlined procedure has minimal side effects for patients and to gain the necessary 80 percent confidence to meet the clinical objectives needed for FDA approval. The big challenges that the COVID-19 pandemic poses to the health care system mean for our study, among other things, that for several weeks now every patient has to be tested, undergo a two-week quarantine and then be tested again. This brings an unavoidable delay to the almost completed current Stage 2a of the study, and by now we expect to complete the current stage still this year and start the final Stage 2b in January.
Commercial Model for Focal Cancer Treatment Centers in the U.S.: Lease Back Partnership
While completing the study, MagForce will begin preparations for commercialization, which is still expected to start in mid or second half of 2021. Our three MagForce USA owned and operated locations in San Antonio, Texas; Seattle, Washington; and Sarasota, Florida will be our primary locations. All three participating clinical trial sites are already fully equipped with the NanoActivator devices, a dedicated and trained staff, and would be in a position to start commercial treatments immediately. Upon completion of the study, the Company plans to have two additional proprietary treatment centers in place. Additional sites will then be opened in strategic locations in the U.S. to enable the treatment of patients locally. MagForce is already in contact with the most important "Active Surveillance Programs" throughout the country to evaluate their desire for an ambulatory NanoActivator.
MagForce USA's commercial model considers two marketing channels: 1) stand-alone Focal Cancer Treatment Centers owned and staffed by MagForce USA. This would allow MagForce USA to bill for the entire procedure as it is standard with for example dialysis treatments; 2) placement of ambulatory NanoActivators in urology clinics, providing the NanoTherm therapy system to the respective clinical site. To facilitate either channel, MagForce USA has established a sale and lease back partnership for U.S. NanoActivators with three-year term each. This will allow MagForce USA to accelerate its commercial plan.
Considering the potential global market, over 500,000 prostate cancer patients could be treated per year and benefit from an effective focal treatment with minimal side effects. The market potential would lie between 3.5 and 12.5 billion USD per year depending on the business model.
Results of operations, net assets and financial position
Revenues amounted to EUR 384 thousand, a strong increase compared to EUR 26 thousand in the previous year. The revenues were generated from the commercial treatment of patients with NanoTherm therapy in Germany in the amount of EUR 212 thousand (previous year: EUR 23 thousand) and NanoTherm and catheter deliveries to subsidiaries in the amount of EUR 173 thousand (previous year: EUR 3 thousand). A total of 11 patients were treated at the German centers and 6 patients in Lublin, Poland in the first half of 2020.
Other own work capitalized amounting to EUR 196 thousand (previous year: EUR 0 thousand) relates to capitalized expenses for preparing the product files for MagForce AG's medical products in accordance with the requirements of the new Medical Device Regulation (MDR).
Other operating income amounted to EUR 332 thousand in the reporting period and was largely at the previous year's level (EUR 329 thousand).
Cost of materials increased from EUR 194 thousand to EUR 286 thousand. The cost of raw materials, supplies and purchased goods as well as purchased services increased to the same extent.
Personnel expenses increased to EUR 2,097 thousand (previous year: EUR 1,846 thousand).
At EUR 1,667 thousand, other operating expenses were EUR 59 thousand higher than in the previous year (EUR 1,608 thousand) and were thus largely at the previous year's level.
The operating result for the first half of 2020 was EUR -3,432 thousand (previous year: EUR -3,610 thousand). The strong increase in revenues contributed significantly to the improved result.
While interest income remained constant at EUR 108 thousand (previous year: EUR 108 thousand), interest expenses rose from EUR 949 thousand to EUR 1,030 thousand due to the expansion of external financing. Write-downs on financial assets increased by EUR 61 thousand and amounted to EUR 521 thousand (previous year: EUR 460 thousand) which relates to the contributions made to finance the operating activities of the subsidiary MT MedTech Engineering GmbH.
The first half of 2020 closed with a net loss of EUR -4,877 thousand. Due to the increased revenues, the result for the period improved by EUR 35 thousand compared to the previous year (EUR -4,912 thousand).
Cash flow from operating activities amounted to EUR -2,290 thousand (previous year: EUR -2,856 thousand). The cash outflow from operating activities was derived indirectly from the net loss for the period. The cash outflows mainly relate to the financing of operating activities.
Cash flow from investing activities amounted to EUR -1,850 thousand (previous year: EUR -785 thousand) and primarily related to the contributions made to provide financial support to the subsidiary MT MedTech Engineering GmbH and payments for the construction of mobile NanoActivators as well as the expenses incurred in preparing the technical documentation for MagForce products.
Cash flow from financing activities amounted to EUR 5,653 thousand (previous year: EUR 3,325 thousand) and is mainly attributable to the payments received in connection with the external financing measures implemented. The payments received were in part offset by cash outflows in the form of interest payments.
At the end of the reporting period, the freely available liquidity amounted to EUR 1,680 thousand (December 31, 2019: EUR 167 thousand). The increase is due to the drawing of the second tranche of the EIB loan and the issue of new convertible bonds.
Outlook and financial prognosis 2020 and beyond
The outlook for the year 2020, as reported in the 2019 annual report, published on June 30, 2020 was reaffirmed by management.
About MagForce AG and MagForce USA, Inc.MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.
For more information, please visit: http://www.magforce.comGet to know our Technology: video (You Tube)Stay informed and subscribe to our mailing list
Disclaimer
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.
T +49-30-308380-77E-Mail: bfrankenberg@magforce.com
30.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de
Continue reading here:
MagForce AG Publishes Financial Results for the First Half of 2020 and Operative Highlights - PharmiWeb.com
Betina Brresen,1 Anders Elias Hansen,2,3 Frederikke Petrine Fliedner,2 Jonas Rosager Henriksen,3 Dennis Ringkjbing Elema,3,4 Malene Brandt-Larsen,5 Lotte Kellemann Kristensen,2 6 Annemarie Thuri Kristensen,1 6 Thomas Lars Andresen,3 Andreas Kjr2,5
1Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg C 1870, Denmark; 2Cluster for Molecular Imaging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen N 2200, Denmark; 3DTU Health Technology, Center for Nanomedicine and Theranostics, Technical University of Denmark, Lyngby, Kgs 2800, Denmark; 4DTU Health Technology, The Hevesy Laboratory, Center for Nuclear Technologies, Technical University of Denmark, Roskilde, 4000, Denmark; 5Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Copenhagen 2100, Denmark; 6Minerva Imaging, Copenhagen N 2200, Denmark
Correspondence: Andreas KjrCluster for Molecular Imaging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, Copenhagen N 2200, DenmarkTel +45 35 32 75 04Fax +45 35 32 75 46Email akjaer@sund.ku.dk
Background: The accumulation of liposome encapsulated chemotherapy in solid cancers is dependent on the presence of the enhanced permeability and retention (EPR) effect. Positron emission tomography (PET) imaging with a liposome encapsulated radioisotope, such as liposome encapsulated Cu-64 (64Cu-liposome) may help to identify tumors with high liposome accumulation, and thereby stratify patients based on expected benefit from liposomal chemotherapy. However, intravenous administration of liposomes without a cytotoxic content is complicated by the accelerated blood clearance (ABC) phenomenon for succeeding therapeutic liposome dosing. Alternative markers for assessing the tumors EPR level are therefore warranted.Materials and Methods: To increase our understanding of EPR variations and to ultimately identify an alternative marker for the EPR effect, we investigated the correlation between 64Cu-liposome PET/CT (EPR effect) and 68Ga-RGD PET/CT (neoangiogenesis), 18F-FDG PET/CT (glycolysis), diffusion-weighted MRI (diffusivity) and interstitial fluid pressure in two experimental cancer models (CT26 and COLO 205).Results: 64Cu-liposome and 68Ga-RGD SUVmax displayed a significant moderate correlation, however, none of the other parameters evaluated displayed significant correlations. These results indicate that differences in neoangiogenesis may explain some EPR variability, however, as correlations were only moderate and not observed for SUVmean, 68Ga-RGD is probably insufficient to serve as a stand-alone surrogate marker for quantifying the EPR effect and stratifying patients.
Keywords: EPR effect, liposome, positron emission tomography, neoangiogenesis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
See the article here:
Noninvasive Molecular Imaging of the Enhanced Permeability and Retenti | IJN - Dove Medical Press
TAMPA, Fla., Oct. 28, 2020 /PRNewswire/ -- The National Academy of Inventors (NAI) has released its sixth video documenting the path from university discovery to public marketplace. This episode in the From Campus to Commerceseries highlights silver nanoparticle technology from the University of Missouri (Mizzou) developed by Dr. Kattesh Katti.
Katti is the recipient of the Hevesy Medal, a highly regarded award in Nuclear Sciences and Medicine. He is also globally known as the "Father of Green Medical Nanotechnology" for his pioneering work combining non-toxic nanoagents with traditional Ayurvedic-Holistic Medicine, used by 65-80 percent of the world's population as a primary source of health care.
In the video, Katti is seen in his lab discussing the impetus for his chosen work. "I wanted to create one product with dual actions of antibiotic/anti-viral properties so that people don't have to use several different agents to decontaminate infected areas."
His discoveries have been enormously successful, especially the timely product NanOLife sanitizer, which kills BOTH bacteria and viruses, including COVID-19.
Over the past three decades, Katti's work has also focused on molecular imaging and therapy in oncology. His gold-based nanomedicine is being used in cancer therapy today. In an NAI webinarearlier this month, he explained that gold, unlike many delivery mechanisms, is non-toxic to the body.
Katti has been recognized by the United Nations/IAEA as the Global Expert in 'Green Nanotechnology' and has won many awards such as the 2016 Person of the Year in Science. He is a Fellow of the National Academy of Inventors as well as a professor at Mizzou.
More information about Dr. Katti's work can be found on his website.
Watch all of the From Campus to Commerce videoson NAI's YouTube channel and check out the Academy's new ScholarShare webinar seriesas well.
About the National Academy of Inventors
The National Academy of Inventorsis a member organization comprising U.S. and international universities, and governmental and non-profit research institutes, with over 4,000 individual inventor members and Fellows spanning more than 250 institutions worldwide. It was founded in 2010 to recognize and encourage inventors with patents issued from the U.S. Patent and Trademark Office (USPTO), enhance the visibility of academic technology and innovation, encourage the disclosure of intellectual property, educate and mentor innovative students, and translate the inventions of its members to benefit society. The NAI works collaboratively with the USPTO and publishes the multidisciplinary journal, Technology and Innovation. http://www.academyofinventors.org.
Media Contact: Jody Santoro[emailprotected]1-813-974-0782
SOURCE National Academy of Inventors
Swansea University Medical Schools Professor Steve Conlan has taken up a key role helping to highlight UK nanomedicine research.
He has been appointed Chair of the British Society for Nanomedicine (BSNM), the UKs leading organisation which seeks to give industry, academia, clinicians and the public access to news of ongoing nanomedicine research throughout the UK.
Professor Conlan, who is the Medical Schools head of enterprise and innovation, explained that the field of nanomedicine the application of nanotechnology to healthcare is still relatively new, but its global benefits are multiplying every year, with 50 nanomedicines already in clinical trials.
He said: Nanomedicine is a growing and diverse area of research providing new and innovative treatments that are benefiting patients on a global scale.
Here at Swansea we have access to cutting-edge technology teamed with world leading researchers and teachers in the field. Through BSNM we will be able to promote and share research ideas and form new collaborations that will benefit the nanomedicine community and aid in the development of much-needed diagnostics and therapeutics.
BSNM aims to explain ongoing science and commercial developments so the public can understand and stay in touch with this exciting area as it impacts future healthcare.
Professor Conlan will share the post with co-chair Dr Tom McDonald, from the University of Liverpool.
One of their first responsibilities is to host a series of online early career researcher events to build on the success of annual events held around the UK over the past 10 years.
The first of these take place on November 25 and 26 and will provide an opportunity for ECRs to showcase innovative research and discuss outputs and opportunities with other researchers and experts in the field of nanomedicine.
It will also offer researchers the chance to network and collaborate with the wider nanomedicine community during interactive breakout sessions.
Junior researchers (PhDs and Post-docs) can share their work through a 15-minute presentation. Anyone interested in taking part should contact [emailprotected] no later than Friday, October 30.
The free event will be held on Zoom and those interested can register to attend via Eventbrite, or at BSNM.
View original post here:
Professor's new role helping to promote nanomedicine across the UK - Wales247
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN: FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the first patient has been injected in its phase I study evaluating NBTXR3 activated by radiation therapy for patients with pancreatic cancer. The trial is a being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson) as part of an ongoing clinical collaboration.
Two additional trials from the clinical collaboration received safe to proceed notifications from the United States Food and Drug Administration (FDA): (i) a phase I study evaluating NBTXR3 activated by radiation therapy for patients with lung cancer amenable to re-irradiation; and (ii) a phase I study evaluating NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer. All current and future trials in this clinical collaboration are sponsored and executed by MD Anderson.
A Phase I Study Evaluating NBTXR3 Activated by Radiation Therapy in Patients with Pancreatic Cancer
Pancreatic cancer is a rare, deadly disease that accounts for approximately 3% of all cancers and has a 5-year survival rate of 9%1.
This pancreatic cancer trial is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the recommended phase 2 dose (RP2D) of NBTXR3 activated by radiation therapy; and (ii) expansion at RP2D.
The patient population will include adults (age 18 years) with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) that are radiographically non-metastatic at screening, and that have not previously received radiation therapy or surgery for pancreatic cancer. Up to 24 subjects will be enrolled and the planned enrollment period is 18 months.
The objectives of the study are the determination of dose-limiting toxicity (DLT), the maximum tolerated dose (MTD), and the RP2D.
Two Additional Phase I Studies in Lung and Esophageal Cancer Pending
A phase I trial investigating NBTXR3 activated by radiation therapy for patients with lung cancer amenable to re-irradiation, and a phase I trial investigating NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer have been deemed safe to proceed by FDA. Safe to proceed notifications are delivered once the agency is satisfied with the information contained in an investigational new drug application (IND) or any additional information or clarification has been provided.
Lung cancer is the second most common cancer type, and the leading cause of cancer death for both men and women. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a 5-year survival rate of 24% worldwide.2
The lung cancer trial is an open-label, two-cohort, prospective phase I study consisting of two parts: (i) a radiation therapy safety lead-in, and NBTXR3 activated by radiation therapy dose-finding to determine the RP2D; and (ii) expansion at the RP2D with toxicity monitoring.
The patient population will include adults (age 18 years) with inoperable, locoregional recurrent (LRR) non-small cell lung cancer (NSCLC) stage IA to IIIC that are radiographically non-metastatic at screening and have previously received definitive radiation therapy. Cohort 1 will evaluate the safety of intensity-modulated radiation therapy (IMRT) monotherapy in 10 patients. Up to 24 subjects will be enrolled in cohort 2. Recruitment is expected to begin in 4Q2020 and the planned enrollment period is 36 months.
Esophageal cancer is the eighth most common cancer type and the sixth most common cause of cancer deaths worldwide. The 5-year survival rate in the US is 20%, and 10% in Europe3.
The esophageal cancer trial is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the RP2D of NBTXR3 activated by radiation therapy with concurrent chemotherapy, as per standard of care; and (ii) expansion at the RP2D with toxicity monitoring.
The patient population will include adults (age 18 years) with stage II-III adenocarcinoma of the esophagus that are treatment nave and radiographically non-metastatic at screening. Up to 24 subjects will be enrolled. Recruitment is expected to begin in 4Q2020 and the planned enrollment period is 24 months.
Next Steps for Clinical Collaboration with MD Anderson
The clinical collaboration between Nanobiotix and MD Anderson includes plans for additional clinical trials across several indications. Beyond the three (3) trials mentioned above, the other trials, including four (4) combination trials with immune checkpoint inhibitors and NBTXR3 activated by radiation therapy, are in preparation and will launch in due time.
***
About NBTXR3
NBTXR3 is a novel radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy. The physical and universal mode of action (MoA) of NBTXR3 is designed to trigger cellular destruction death and adaptive immune response.
NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers. In February 2020, the United States Food and Drug Administration granted the regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.
Nanobiotix is also running an Immuno-Oncology development program. The Company has launched a Phase I clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets) from any primary cancer eligible for anti-PD-1 therapy.
Other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and pancreatic cancer. The Company is also engaged in a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to further expand the NBTXR3 development program.
About NANOBIOTIX: http://www.nanobiotix.com
Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.
Nanobiotixs novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.
Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.20-010 on May 12, 2020 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
1 https://www.cancer.net/cancer-types/pancreatic-cancer/statistics
2 https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics
3 https://www.cancer.net/cancer-types/esophageal-cancer/statistics
View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005825/en/
NanobiotixCommunications DepartmentBrandon OwensVP, Communications+1 (617) 852-4835
Investor Relations DepartmentRicky BhajunSenior Manager, Investor Relations+33 (0)1 79 97 29 99
Media RelationsFrance Ulysse CommunicationPierre-Louis Germain
+ 33 (0)6 64 79 97 51
plgermain@ulysse-communication.com
The rest is here:
NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA...
Given the debilitating impact of COVID-19 (Coronavirus) on the Healthcare Nanotechnology (Nanomedicine) market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Healthcare Nanotechnology (Nanomedicine) market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.
The report provides both quantitative and qualitative information of global Healthcare Nanotechnology (Nanomedicine) market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Healthcare Nanotechnology (Nanomedicine) is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Healthcare Nanotechnology (Nanomedicine) market was valued at USD _ million/billion.
This research report based on Healthcare Nanotechnology (Nanomedicine) market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Healthcare Nanotechnology (Nanomedicine) market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Healthcare Nanotechnology (Nanomedicine) industry.
Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370
Healthcare Nanotechnology (Nanomedicine) Market Overview:
The Research projects that the Healthcare Nanotechnology (Nanomedicine) market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.
Leading manufacturers of Healthcare Nanotechnology (Nanomedicine) Market:
Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.
Key geographies evaluated in this report are:
Key features of this report
Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370
Some important highlights from the report include:
For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370
The Questions Answered by Healthcare Nanotechnology (Nanomedicine) Market Report:
And Many More.
Read the rest here:
R&D Activities to Fast-track the Growth of the Healthcare Nanotechnology (Nanomedicine) Market Between 2015 2021 - PRnews Leader
(Sep, 2020) United Kingdom, The report titled Nanorobots Market: Size, Trends and Forecasts (2020-2026), delivers an in-depth analysis of the Nanorobots Industry by considering there type, application, market value, by production capacity, by companies, by region, etc.
The report assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the Nanorobotsindustry. Growth of the overall Nanorobotsmarket has also been forecasted for the period 2020-2026, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
Get Exclusive Sample copy on Nanorobots Marketis available athttps://www.worldwidemarketreports.com/sample/366582
NanorobotsMarket report analyses the impact of Coronavirus (COVID-19) on theNanorobotsindustry.
Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.
COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.
If you are investor/shareholder in theNanorobotsMarket, the provided study will help you to understand the growth model ofNanorobotsIndustry after impact of COVID-19. Request for sample report (including ToC, Tables and Figures with detailed information) @https://www.worldwidemarketreports.com/covidimpact/366582
The research report segments the market from a relevancy perspective into the below segments and sub-segments with the quantitative analysis done from 2017 to 2026 considering 2019 as the base year for the research. Compounded Annual Growth Rate (CAGR) for each respective segment and sub-segment is calculated for the forecast period from 2019 to 2026 to provide a reference for growth potential.
Nanorobotsmarket segmented on the basis of Product Type:Nanomanipulator, Bio-Nanorobotics, Magnetically Guided, Bacteria-Based
Nanorobotsmarket segmented on the basis of Application: Nanomedicine, Biomedical, Others
The major players profiled in this report include:Bruker, Jeol, Thermo Fisher, Ginkgo Bioworks, Oxford Instruments, Ev Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Xidex, Synthace, Park Systems, Smaract, Nanonics Imaging, Novascan Technologies, Angstrom Advanced, Hummingbird Scientific, Nt-Mdt Spectrum Instruments, Witec
Get Chance of 20% Extra Discount, If your Company is Listed in Above Key Players List;https://www.worldwidemarketreports.com/discount/366582
Regional Coverage of theNanorobotsMarket:
Reasons to PurchaseNanorobotsMarket Research Report
:DOWNLOAD COMPLETE PDF BROCHURE:
Contact Us:
Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]
Follow this link:
Mobile Nanorobots Market Size, Share & Trends Analysis Report By Product Types, And Applications Forecast To 2026: Bruker, Jeol, Thermo Fisher,...
Nanomedicine Market Report Delivering Growth Analysis with Key Trends of Top Companies (2020-2026)
A comprehensive research study on the Nanomedicine Marketwas recently published by Market Report Expert. This is an up-to-date report, covering the current COVID-19 impact on the market. The Coronavirus (COVID-19) has affected every aspect of life globally and thus altering the global market scenario. The changes in the market conditions are drastic. The swiftly changing market scenario and initial and future assessment of the impact on Nanomedicine market is covered in the report.The Nanomedicine Market report is a precise and deep-dive study on the current state that aims at the major drivers, market strategies, and imposing growth of the key players. Worldwide Nanomedicine Industry also offers a granular study of the dynamics, segmentation, revenue, share forecasts, and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Nanomedicine industry.
The Global Nanomedicine Market poised to grow from US$ XX million in 2020 to US$ XX million by 2026 at a compound annual growth rate (CAGR) of XX% during the projection period of 2020-2026.
An Outline of the Major Key Players covered in this Report:
Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences
Get Free LatestPDF Template of this Report(Including Covid-19 impact analysis on overall industry Forecast, Size, Share, CAGR and more.)@ https://www.marketreportexpert.com/report/Nanomedicine/13084/sample
Note: We can also provide market report in German/French Language.
The report puts together a succinct analysis of the growth drivers influencing the current business scenario across various regions and countries. Substantial information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present a collaborative prediction. Additionally, this report encompasses a precise competitive analysis of major market players, innovative companies, and their strategies during the projection timeline.
The latest report on the Nanomedicine Market consists of an analysis of this industry and its type, application, and other segments. As per the report, the market is estimated to gain significant returns and register substantial y-o-y growth during the forecast period of 2020-2026.
Majortype, primarily split into
Quantum dotsNanoparticlesNanoshellsNanotubesNanodevices
Major applications/end users, including
Segmentation encompasses oncologyInfectious diseasesCardiologyOrthopedicsOthers
According to the report, the study offers details regarding the valuable estimations of the market such as market size, sales capacity, and profit projections. The report documents factors such as drivers, restraints, and opportunities that impacts the remuneration of this market.
Feel Free! Ask Our Industry Expert For Discount on this Report(Note: Our reports include the analysis of the impact of COVID-19 on this industry. Our updated sample pages shows impact of Covid-19 on Industry trends. Also we are offering 20% discount.): https://www.marketreportexpert.com/report/Nanomedicine/13084/inquiry
The research offers an analysis of the geographical landscape of the Nanomedicine Market, which is divided into regions such as North America, Europe, Asia Pacific, South America, and the Middle East & Africa. The segment includes data about several parameters related to the regional contribution such as market share, application share, type share, key companies in respective regions, market share of key companies in regional market, growth rate and revenue of the regional market, sales, production, and consumption of the respective Nanomedicine market.
Major Highlights of TOC Covers:
Nanomedicine Market 2020, Nanomedicine Market size, Nanomedicine Market share, Nanomedicine Market analysis, Nanomedicine Market forecast, Nanomedicine Market trends, Nanomedicine Market Research report, Nanomedicine application, Nanomedicine Trends, Nanomedicine Market growing CAGR, Nanomedicine Market Competitive Landscape, Nanomedicine Market Growth
Information related to the growth rate, revenue, sales, production, consumption, during the forecast period is included in the report. The Nanomedicine Market report claims that the industry is projected to generate significant revenue and sales during the forecast period. The report consists of information related to the market dynamics such as challenges involved in this vertical, growth opportunities, and driving factors affecting the market.
About Us
Market Report Expert is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports.
Contact USJames ThompsonMarket Report ExpertPhone: +1-816-301-6258Email inquiry@marketreportexpert.comWeb:-https://www.marketreportexpert.com
Read the original:
2020 Trending: Nanomedicine Market is Thriving Worldwide By Size, Revenue, Emerging Trends and Top Growing Companies 2026| Combimatrix, Ablynx,...
Cancer is a complex disease to treat, and yet the operating principle of many current treatments is to simply kill healthy cells a little slower than cancerous ones. In response, scientists at the University of Electronic Science and Technology of China have developed a sophisticated nanoparticle-based treatment. Their theranostic nanoparticles carry an anti-cancer drug cargo, and showcase multiple cutting-edge nanomedicine technologies to enhance the drug's efficacy, including selective drug delivery, photoactive agents, and even signal-jamming genetic material.
The researchers have designed each individual nanoparticle to be a toolbox for cancer therapy, able to passively and actively target tumours (Biomater. Sci. 5 1001). The nanoparticles can act as contrast agents for both magnetic resonance imaging and X-ray, they deliver a concentrated dose of anti-cancer drugs, and they also thwart the cancer's attempts at developing immunity to the drug. They even deliver a photosensitizer that can be used to specifically weaken cancerous tissue by photodynamic treatment.
Yiyao Liu and colleagues demonstrated the efficacy of their nanodevices in vitro and in vivo on a range of cell lines and on tumours in living mice. They found that their nanoparticle drug-delivery technique effectively stopped tumour growth, whereas tumours in mice treated with the drug alone grew at a rate half that of a control group that had not been treated.
The nanoparticles are complex, many layered spheres. Protected by a jacket of natural polymer is a nugget of silica, holey like a sponge and soaked in doxorubicin, a common anti-cancer drug, along with the photosensitizer. The polymer jacket is pH sensitive so that it falls off in the acidic microenvironment of the tumour, only then releasing the active cargo.
Doxorubicin has two flaws. Firstly, it works by slotting in-between DNA base pairs to stop the replication process needed for cells to divide. This kills cells that need to duplicate quickly, such as cancerous cells, but harms many healthy cell types too. Secondly, it triggers the body's natural defences, causing cells to over express p-glycoprotein, a microscale pump that removes toxic molecules like doxorubicin from cells, and making the drug less and less effective against cancer.
The scientists at The University of Electronic Science and Technology of China countered both of these flaws. Healthy cell exposure is reduced by the polymer jacket, which makes sure the drug is only released under the conditions expected in a tumour. The jacket itself is covered in signal-jamming RNA to inhibit the expression of the cellular pumps, keeping the doxorubicin trapped inside the cells to allow the drug to work for longer. This impressive display of multifunctional nanoparticle design and synthesis demonstrates the power of nanomedicine for producing synergistic effects, offering new solutions to previously unsurmountable problems.
Denser nanoparticles boost drug penetration Personalize nanoparticles to target tumours Inhaled nanoparticles target lung cancer Nanoneedles deliver therapeutics into cells
See the original post here:
Nanomedicine enables all-in-one cancer treatment - Medical Physics Web (subscription)
May 24, 2017 by Maria Kavallaris, Joshua Mccarroll And Thomas P Davis, The Conversation Therapies on a nano scale rely on engineered nanoparticles designed to package and deliver drugs to exactly where theyre needed. Credit: shutterstock.com
A recent US study of people treated for cancer as children from the 1970s to 1999 showed that although survival rates have improved over the years, the quality of life for survivors is low. It also showed this was worse for those who were treated in the 1990s.
About 70% of childhood cancer survivors experience side effects from their treatment, including secondary cancers. And as survival rates improve, the worldwide population of childhood cancer survivors is growing.
Side effects cause stress for survivors and families and increase demand on health systems. But an emerging area of medicine, nanomedicine, offers hope for better children's cancer treatment that will have fewer side effects and improve quality of life for survivors.
What is nanomedicine?
Nanomedicine is the application of nanomaterials, or nanoparticles, to medicine. Nanoparticles are a form of transport for drugs and can go places drugs wouldn't be able to go on their own.
Nano means tiny. A nanometre (nm) is one-billionth of a metre. Nanoparticles used for drug delivery are usually in the 20 to 100 nanometre range, although this can vary depending on the design of the nanoparticle.
Nanoparticles can be engineered and designed to package and transport drugs directly to where they're needed. This targeted approach means the drugs cause most harm in the particular, and intended, area of the tumour they are delivered to. This minimises collateral damage to surrounding healthy tissues, and therefore the side effects.
The first cancer nanomedicine approved by the US Food and Drug Administration was Doxil. Since 1995, it has been used to treat adult cancers including ovarian cancer, multiple myeloma and Karposi's sarcoma (a rare cancer that often affects people with immune deficiency such as HIV and AIDS).
Currently, there is a stream of new nanomedicine treatments for adult cancers in clinical trials (trials in humans), or on the market. But only a limited number of these have been approved for children's cancers, although this is arguably where nanomedicine's strengths could have the most benefit.
How does nanomedicine work?
The nanoparticle drug-delivery systems can work in different ways. Along with carrying the drug for delivery, nanoparticles can be engineered to carry specific compounds that will let them bind, or attach, to molecules on tumour cells. Once attached, they can safety deliver the drug to the specific tumour site.
Nanoparticles can also help with drug solubility. For a drug to work, it must be able to enter the bloodstream, which means it needs to be soluble. For example, the cancer drug paclitaxel (Taxol) is insoluble so has to be dissolved in a delivery agent to get into the blood. But this agent can cause allergic reactions in patients.
To overcome these issues, chemists have developed a nanoparticle out of the naturally occurring protein albumin. It carries the paclitaxel and makes it soluble but without the allergic reactions.
Tumours commonly have disordered and leaky blood vessels sprouting through and off them. These vessels allow chemotherapy drugs to readily enter the tumour, but because chemotherapy molecules are so small, they also diffuse through the vessels and out of the tumour, attacking surrounding tissues. Nanoparticles are larger molecules that get trapped inside the tumour, where they do all the damage.
Once they have delivered their drug cargo to cells, nanoparticles can be designed to break down into harmless byproducts. This is particularly important for children who are still developing.
Types of nanoparticles
Nanoparticles vary in characteristics like shape and size. Researchers need to match the right nanoparticle to the drug it's to deliver and the particular tumour.
An array of nanoparticle structures are currently being engineered. One example of an interesting structure is the shape of a DNA origami. Because DNA is a biological material, nanoparticles engineered into DNA origami shapes won't be seen as foreign by the immune system. So these can transport a drug to diseased cells while evading the body's immune system, therefore lessening the side effects of drugs.
Another example of nanomedicine structures are polymeric nanocarriers. We have recently identified a gene that promotes the growth of tumours, cancer spread and resistance to chemotherapy in pancreatic cancers.
We used a nanomedicine called a polymeric nanocarrier and combined it with a drug that silences the cancer gene. We packaged this up to form a nanomedicine and delivered the drugs into the tumour.
These nanomedicines reduced the expression of the cancer gene, blocked tumour growth and reduced the spread of pancreatic cancer. But we also showed that polymeric nanocarriers can be combined in the lab with other gene-silencing drugs. This means the method can be used for a range of other gene-based cancers.
How can nanomedicines help treat kids' cancer?
In standard treatment for children's cancer, chemotherapy drugs are often prescribed at the maximum tolerable dose for a child's age or size, based on adult dosages. But children aren't small adults. The processes underlying children's growth and development might lead to a different effect and response to a chemotherapy drug not seen in adults.
Also, if a child becomes resistant to a drug and they're on the maximum tolerable dose, there's no scope to increase it without toxic side effects. By packaging up drugs and moving them through the body directly to diseased cells to reduce collateral damage, in theory, nanomedicine allows higher doses of drugs to be used.
Nanomedicine has great potential to safely treat children's cancer. However, it is currently stymied by too little research. About two-thirds of research attention in nanomedicine therapeutics, of more 250 nanomedicine products, is focused on cancer. Yet this isn't translating into new cancer treatments for children coming to market.
But we are making progress. Our work is exploring the design of nanoparticles to deliver gene-silencing drugs to treat the most common brain cancer in children medulloblastoma.
We're also working on nanomedicines for other significant childhood cancers. These include drug-refractory acute lymphoblastic leukaemia, the most common childhood cancer, and neuroblastoma, the cancer that claims more lives of those under five than any other.
Explore further: New nanotechnology application for difficult-to-treat cancers
This article was originally published on The Conversation. Read the original article.
A new treatment combining shock waves with nanoparticles can successfully treat tumours that are difficult to target using conventional chemotherapy. This is the first time this combined therapy has been tested in live animals. ...
Australian cancer researchers have developed a highly promising nanomedicine that could improve treatment for pancreatic cancer the most deadly cancer in Australia.
Nanomedicine has the potential to help personalize cancer treatments and reduce side effects of therapeutic drugs. While some progress has been made toward the latter goal, customized treatments are still hard to come by. ...
A Mayo Clinic research team has developed a new type of cancer-fighting nanoparticle aimed at shrinking breast cancer tumors, while also preventing recurrence of the disease. In the study, published today in Nature Nanotechnology, ...
New research carried out by drug delivery experts at The University of Nottingham has highlighted more advantages to using nanoparticles for the delivery of cancer drugs.
Targeting cancer cells for destruction while leaving healthy cells alonethat has been the promise of the emerging field of cancer nanomedicine. But a new meta-analysis from U of T's Institute of Biomaterials & Biomedical ...
In the May issue of PLOS Computational Biology, scientists from UC San Diego and the University of Notre Dame report on a study that could open up the field for nanopore-based protein identification and eventually proteomic ...
Researchers at the University of Central Florida have developed a new color changing surface tunable through electrical voltage - a breakthrough that could lead to three times the resolution for televisions, smartphones and ...
Researchers from North Carolina State University have discovered a technique for controlling light with electric fields.
Dr. Saw-Wai Hla and Dr. Eric Masson are thrilled with their team's performance in the world's first nanocar race in April, but for them, it was a fun starting point to a much larger goal.
Researchers from AMOLF and Swiss EPFL have shown that the surface of minuscule water drops surrounded by a hydrophobic substance such as oil is surprisingly ordered. At room temperature, the surface water molecules of these ...
Computers process and transfer data through electrical currents passing through tiny circuits and wires. As these currents meet with resistance, they create heat that can undermine the efficiency and even the safety of these ...
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Go here to see the original:
What is nanomedicine, and how can it improve childhood cancer treatment? - Phys.Org